Colin Bristow
Stock Analyst at UBS
(1.12)
# 3,634
Out of 4,944 analysts
102
Total ratings
32.2%
Success rate
-12.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $120.14 | -6.78% | 4 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $582 → $553 | $395.92 | +39.67% | 15 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $48.17 | +66.08% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.09 | +61.81% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.66 | +51.38% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $15.89 | +6.99% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $289.33 | +10.25% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.27 | +214.96% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.68 | +90.22% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $25.16 | +11.29% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $82.71 | +45.09% | 6 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $135.19 | +49.42% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $5.60 | +185.71% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $561.55 | +95.71% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $20.40 | +718.63% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $660.49 | -36.41% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $4.27 | -53.16% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.37 | +659.49% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $201.47 | -27.53% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $47.85 | +56.74% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.33 | +1,015.88% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $6.40 | +40.63% | 1 | Aug 23, 2021 |
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $120.14
Upside: -6.78%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582 → $553
Current: $395.92
Upside: +39.67%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $48.17
Upside: +66.08%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.09
Upside: +61.81%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.66
Upside: +51.38%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $15.89
Upside: +6.99%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $289.33
Upside: +10.25%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.27
Upside: +214.96%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.68
Upside: +90.22%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $25.16
Upside: +11.29%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $82.71
Upside: +45.09%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $135.19
Upside: +49.42%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $5.60
Upside: +185.71%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $561.55
Upside: +95.71%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $20.40
Upside: +718.63%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $660.49
Upside: -36.41%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $4.27
Upside: -53.16%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.37
Upside: +659.49%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $201.47
Upside: -27.53%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $47.85
Upside: +56.74%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.33
Upside: +1,015.88%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $6.40
Upside: +40.63%